Well after all that SA author is pro Gilead so anything that has the potential to eat into its market share he will not praise. As for the company not being bought out it's like you said it is not one sided. Both parties have to come to an agreement. Plus we are not behind the scenes so we don't know if Gilead has made albeit a small offer or not. Maybe CYDY management wants more than what Gilead has to offer. Maybe Gilead only wants to pay $500 mil to the buy the company? Nobody knows because we are not on the inside. But the data to date and the patients with reduced viral loads speak for themselves. I know what the company is worth and IMO management taking anything less than $1B or $2B would be shameful.
News 
Market Data 
Discover 
AI
